AngioDynamics, Inc. (ANGO)

NMS – Real Time Price. Currency in USD

10.90

+0.06 (0.55%)

At close: May 12, 2026, 4:00 PM EDT

10.65

-0.25 (-2.25%)

After-hours: May 12, 2026, 4:21 PM EDT

06.05.2026

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

20.04.2026

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

10.04.2026

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

08.04.2026

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

06.04.2026

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.

05.04.2026

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.

02.04.2026

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

02.04.2026

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.

19.02.2026

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expan.

05.02.2026

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent.

03.02.2026

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will convene leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum, as the Company advances multiple cardiovascular programs following recent FDA regulatory milestones into active clinical engagemen.

AngioDynamics, Inc. (ANGO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AngioDynamics, Inc. (ANGO)

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Search stocks

AngioDynamics, Inc. (ANGO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AngioDynamics, Inc. (ANGO)

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance